HC Wainwright Raises Kyverna Therapeutics (NASDAQ:KYTX) Price Target to $25.00

Kyverna Therapeutics (NASDAQ:KYTX) had its price target hoisted by analysts at HC Wainwright from $20.00 to $25.00 in a report released on Friday, MarketBeat.com reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target indicates a potential upside of 132.77% from the stock’s current price.

KYTX has been the subject of several other research reports. JPMorgan Chase & Co. lowered their target price on shares of Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research note on Wednesday. Wall Street Zen downgraded shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Kyverna Therapeutics in a report on Friday, March 27th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $30.00.

Kyverna Therapeutics Price Performance

NASDAQ:KYTX opened at $10.74 on Friday. Kyverna Therapeutics has a 52 week low of $2.06 and a 52 week high of $13.67. The stock’s fifty day moving average is $9.03 and its two-hundred day moving average is $8.38. The company has a market capitalization of $652.88 million, a P/E ratio of -3.27 and a beta of 2.05. The company has a quick ratio of 7.75, a current ratio of 8.15 and a debt-to-equity ratio of 0.13.

Kyverna Therapeutics (NASDAQ:KYTX) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.09. Equities analysts expect that Kyverna Therapeutics will post -3.18 EPS for the current year.

Institutional Trading of Kyverna Therapeutics

Hedge funds have recently made changes to their positions in the business. Public Employees Retirement System of Ohio acquired a new position in shares of Kyverna Therapeutics in the third quarter valued at approximately $28,000. Grey Ledge Advisors LLC acquired a new stake in Kyverna Therapeutics during the 1st quarter worth approximately $86,000. EntryPoint Capital LLC purchased a new position in Kyverna Therapeutics in the 4th quarter valued at approximately $94,000. Phoenix Wealth Advisors boosted its position in Kyverna Therapeutics by 17.1% in the 4th quarter. Phoenix Wealth Advisors now owns 12,300 shares of the company’s stock valued at $116,000 after buying an additional 1,800 shares during the period. Finally, Ameriprise Financial Inc. acquired a new position in shares of Kyverna Therapeutics in the third quarter worth $77,000. Institutional investors and hedge funds own 18.08% of the company’s stock.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical?stage biotechnology company dedicated to developing engineered regulatory T?cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen?specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.